<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971889</url>
  </required_header>
  <id_info>
    <org_study_id>21-02-1069</org_study_id>
    <nct_id>NCT04971889</nct_id>
  </id_info>
  <brief_title>Diabetes Medical Nutrition Therapy in Southeastern African American Women</brief_title>
  <official_title>Diabetes Medical Nutrition Therapy in Southeastern African American Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meharry Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Matthew Walker Comprehensive Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meharry Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-arm randomized controlled trial design will be used. Participants will include 291&#xD;
      African American women with type 2 diabetes that are at risk for development and/or&#xD;
      progression of diabetes complications. Both arms, diabetes medical nutrition therapy (MNT)&#xD;
      and diabetes MNT plus motivational interviewing (MI), will include: 1) a 3-month active&#xD;
      intervention period of six biweekly (every other week), group-based, trained&#xD;
      nutritionist-facilitated sessions; 2) a 3-month maintenance intervention period, which will&#xD;
      include one group-based maintenance support session; and 3) a 6-month inactive period (no&#xD;
      contact). The differences between arms is the integration of culturally-adapted MI exercises&#xD;
      during the diabetes MNT plus MI active and maintenance intervention periods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline</time_frame>
    <description>Widely-utilized high performance liquid chromatography methods will be used to measure glycemic control from whole blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>Widely-utilized high performance liquid chromatography methods will be used to measure glycemic control from whole blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Widely-utilized high performance liquid chromatography methods will be used to measure glycemic control from whole blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>Widely-utilized high performance liquid chromatography methods will be used to measure glycemic control from whole blood samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Calculated measure of body max index from height/weight measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Body Mass Index</measure>
    <time_frame>3 months</time_frame>
    <description>Calculated measure of body max index from height/weight measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Body Mass Index</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated measure of body max index from height/weight measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Body Mass Index</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated measure of body max index from height/weight measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>Baseline</time_frame>
    <description>Standard enzymatic laboratory procedures will be used to assess total cholesterol, HDL cholesterol, and triglycerides from whole blood. LDL will be calculated based on total cholesterol and HDL values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline LDL Cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Standard enzymatic laboratory procedures will be used to assess total cholesterol, HDL cholesterol, and triglycerides from whole blood. LDL will be calculated based on total cholesterol and HDL values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline LDL Cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>Standard enzymatic laboratory procedures will be used to assess total cholesterol, HDL cholesterol, and triglycerides from whole blood. LDL will be calculated based on total cholesterol and HDL values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline LDL Cholesterol</measure>
    <time_frame>12 months</time_frame>
    <description>Standard enzymatic laboratory procedures will be used to assess total cholesterol, HDL cholesterol, and triglycerides from whole blood. LDL will be calculated based on total cholesterol and HDL values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>A sphygmometer will be assessed to assess systolic blood pressure fifteen minutes after participant is in a seated position with their arm elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Systolic Blood Pressure</measure>
    <time_frame>3 months</time_frame>
    <description>A sphygmometer will be assessed to assess systolic blood pressure fifteen minutes after participant is in a seated position with their arm elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>A sphygmometer will be assessed to assess systolic blood pressure fifteen minutes after participant is in a seated position with their arm elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Systolic Blood Pressure</measure>
    <time_frame>12 months</time_frame>
    <description>A sphygmometer will be assessed to assess systolic blood pressure fifteen minutes after participant is in a seated position with their arm elevated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Carbohydrate Management Attitude Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for carbohydrate management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Carbohydrate Management Attitude Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for carbohydrate management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Carbohydrate Management Attitude Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for carbohydrate management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Carbohydrate Management Attitude Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for carbohydrate management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fat Management Attitude Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for dietary fat management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Fat Management Attitude Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for dietary fat management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Fat Management Attitude Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for dietary fat management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Fat Management Attitude Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Uses a Likert question format (n=12) and assesses attitudes and motivation for dietary fat management.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes Empowerment Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Uses a Likert question format (n=8) and assesses motivation for overall diabetes self-care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Diabetes Empowerment Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Uses a Likert question format (n=8) and assesses motivation for overall diabetes self-care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Diabetes Empowerment Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Uses a Likert question format (n=8) and assesses motivation for overall diabetes self-care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Diabetes Empowerment Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Uses a Likert question format (n=8) and assesses motivation for overall diabetes self-care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Problem Areas in Diabetes Scale Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Uses a Likert question (n=20) format and assesses patients' problems in applying various self-care areas, including dietary self-care skills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Problem Areas in Diabetes Scale Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Uses a Likert question (n=20) format and assesses patients' problems in applying various self-care areas, including dietary self-care skills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Problem Areas in Diabetes Scale Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Uses a Likert question (n=20) format and assesses patients' problems in applying various self-care areas, including dietary self-care skills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Problem Areas in Diabetes Scale Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Uses a Likert question (n=20) format and assesses patients' problems in applying various self-care areas, including dietary self-care skills.</description>
  </other_outcome>
  <other_outcome>
    <measure>Situational Obstacles to Dietary Adherence Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Uses a Likert question (n=6) format and assesses self-efficacy in adhering to dietary recommendations and managing situations that make adherence challenging (e.g., social activities including few healthy food options.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Situational Obstacles to Dietary Adherence Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Uses a Likert question (n=6) format and assesses self-efficacy in adhering to dietary recommendations and managing situations that make adherence challenging (e.g., social activities including few healthy food options.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Situational Obstacles to Dietary Adherence Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Uses a Likert question (n=6) format and assesses self-efficacy in adhering to dietary recommendations and managing situations that make adherence challenging (e.g., social activities including few healthy food options.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline Situational Obstacles to Dietary Adherence Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Uses a Likert question (n=6) format and assesses self-efficacy in adhering to dietary recommendations and managing situations that make adherence challenging (e.g., social activities including few healthy food options.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetes MNT plus MI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>--Group-based dietary/dietary motivation intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes MNT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Group-based dietary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabetes MNT</intervention_name>
    <description>Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake</description>
    <arm_group_label>Diabetes MNT</arm_group_label>
    <arm_group_label>Diabetes MNT plus MI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing</intervention_name>
    <description>Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise</description>
    <arm_group_label>Diabetes MNT plus MI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African American&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes for at least 6 months&#xD;
&#xD;
          -  At risk for development and/or progression of diabetes complications (HbA1c ≥ 7.0% AND&#xD;
             either systolic blood pressure ≥130, LDL cholesterol ≥ 100, or BMI ≥ 30).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        --Observed or diagnosed psychotic disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identification</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephania Miller-Hughes, PhD</last_name>
    <phone>16153275666</phone>
    <email>smiller@mmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Matthew Walker Comprehensive Health Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katina Beard, MSPH</last_name>
      <email>kbeard@mwchc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephania Miller-Hughes, PhD, MS, MSCI</last_name>
      <email>smiller@mmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meharry Medical College</investigator_affiliation>
    <investigator_full_name>Stephania T. Miller-Hughes</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

